The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS(Q61K) melanoma

Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important in cancer, especially both BRAF(WT) and B...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Simbulan-Rosenthal, Cynthia M., Dakshanamurthy, Sivanesan, Gaur, Anirudh, Chen, You-Shin, Fang, Hong-Bin, Abdussamad, Maryam, Zhou, Hengbo, Zapas, John, Calvert, Valerie, Petricoin, Emanuel F., Atkins, Michael B., Byers, Stephen W., Rosenthal, Dean S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2017
Pynciau:
Priority Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355037/
https://ncbi.nlm.nih.gov/pubmed/28157711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14990
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg